简介:Objective:ThisstudyexaminedHerpesSimplexVirus(HSV)subclinicalsheddinginthegenitaltractofpatientswithgenitalherpes(GH)ornon-gonoccalurethritis(NGU).Method:SwabswerecollectedafterexposuretorashandgenitaltractduringGHrelapseorremissiononaweeklybasisforfourtosixweeks.NGUpatientswithnegativechlamydiaandmycoplasmatestswerealsoswabbedforasimilarduration.AllswabsunderwentHSVDNAdetectionwithquantitativePCR.Result:TherewasasignificantdifferenceintherateofasymptomaticHSVsheddinginurinarytractscomparingGHandthecontrolgroupandcomparingNGUandthecontrolgroup(P<0.05).TherateofHSVsheddingwas22%,9.8%and3.3%forGH,NGUandcontrolgroupsrespectively.TherateofHSVsheddingwas21.7%(20/92)forpatientswithactiveGHand23%forthoseinremission.TheHSVpositiveratewassignificantlyhigherinthegroupwithpatientswhohadmorethansixrelapseswithinoneyearcomparedtothegroupofpatientswithlessthansixGHrelapses.Conclusion:ThereisHSVsubclinicalsheddingintheirgenitaltractduringactiveGHandremission.SubclinicalHSVsheddingismorecommoninpatientswithmorethansixGHrelapsesperyearcomparedtoGHpatientswithfewerrelapses.Approximately9.9%ofNGUpatientswithnegativechlamydia,mycoplasmatestingwasfoundtohavesubclinicalHSVinfection.
简介:EthicsinChinesesexuallytransmittedinfectionresearcharefundamental.SomerecentHarvardgeneticsresearchinAnhuiProvinceshowshowextremelywealthyandpowerfulresearcherscanexploitpoorruralfarmersinChina.AfterseveralyearsofcontroversyandastatementfromtheHarvardpresidentsayingthatthegeneticsexperimentswere"badlywrong",therearestillquestionsaboutforgedinformedconsent(ChinaDaily2003,AHSRP2004).Sincethesegeneticsprojectswereinitiallydiscovered,theUSgovernmentestablishedanewofficetomonitorforeignresearch(Nelson2001).TheobviouslyflawedinternationalresearchcollaborationallowsagoodopportunitytoconsiderthecurrentstateofethicsandrightsinChineseSTIresearch,andestablishastandardforevaluationofresearchatCJSTI.ThisarticlewillexplainseveralcurrentpracticesinChineseSTIresearch,andthenintroduceseveralinternationallyrecognizedstandardsforthinkingaboutpatient'srightsindevelopingcountries.
简介:目的:通过STI571治疗慢性粒细胞白血病,观察其在慢性期.加速期,急变期的疗效,探讨其与各期预后的关系。方法:采用STl571400mg?800mg/d,对住院29例患者连续口服1—12个月。结果:9例慢性粒细胞白血病慢性期分别口服1—4个月,均为完全缓解.3例加速期分别口服1—2个月,其中2例部分缓解,1例未缓解,17例急变期分别口服2—12个月。其中4例达到完全缓解,2例部分缓解,11例未缓解。结论:STI571治疗慢性粒细胞白血病的愦巨期、加速期、急变期都有明显疗效。但加速期、急变期与慢性期相比疗效差,毒副作用多。